Article Text

other Versions

PDF
Sildenafil exposure in neonates with pulmonary hypertension after administration via a nasogastric tube
  1. Maurice J Ahsman1,
  2. Bregje C M Witjes1,
  3. Enno D Wildschut2,
  4. Ilona Sluiter2,
  5. Arnold G Vulto1,
  6. Ron A A Mathot1,*,
  7. Dick Tibboel2
  1. 1 Dept. of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, Netherlands;
  2. 2 Dept. of Pediatric Surgery, Sophia Children's Hospital, Erasmus University Medical Center, Rotterdam, Netherlands
  1. Correspondence to: Ron Mathot, Hopital Pharmacy, Erasmus UNiveristy Medical Center, PO Box 2040, Rotterdam, 3000CA, Netherlands; r.mathot{at}erasmusmc.nl

Abstract

Objective: To describe the pharmacokinetics and exposure of oral sildenafil in neonates (2-5 kg) with pulmonary hypertension.

Design: We included eleven neonates (body weight 2-5kg, PNA 2-121 days) who received sildenafil and ECMO-treatment for pulmonary hypertension. Sildenafil capsules were given via a nasogastric tube. Blood samples were collected via a pre-existing arterial line to quantify sildenafil and metabolite plasma levels (219 samples). Nonlinear mixed effects modelling was used to describe sildenafil (SIL) and desmethylsildenafil (DMS) pharmacokinetics.

Results: A one-compartment model was suitable for both SIL and DMS. Inter- and intrapatient variability for clearance at 100% bioavailability were 87% and 27% (SIL) and 62% and 26% (DMS). Patient weight, postnatal age and post-ECMO time did not explain variability. Concomitant fluconazole use was associated with a 47% reduction in sildenafil clearance. The exposure expressed as AUC24 (SIL+DMS) ranged from 625 to 13579 ng*h/mL. An oral dose of 4.2 mg/kg/24h would lead to a median AUC24 (SIL+DMS) of 2650 ng*h/mL equivalent to 20 mg t.i.d. in adults. Interpatient variability was large, with a simulated AUC24 (SIL+DMS) range (10th and 90th percentiles ) of 1000 - 8000 ng*h/mL.

Conclusions: Sildenafil pharmacokinetics are highly variable in post-ECMO neonates and infants. In a median patient, the current dose regimen of 0.5 – 2.0 mg/kg q.i.d. leads to an exposure comparable to the recommended adult dose of 20 mg t.i.d. Careful dose titration, based on efficacy and the occurrence of hypotension, remains necessary. Follow-up research should include appropriate pharmacodynamic endpoints, with a population PK/PD analysis to assign a suitable exposure window or target concentration.

Statistics from Altmetric.com

Footnotes

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.